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Abstract
The published literature on the evidence for a mutational meltdown of life was reviewed. Although 
only a small percent of all mutations are detrimental enough to cause disease, the total number 
occurring in each generation is significant. It was once concluded that the vast majority of all 
mutations were neutral, but evidence now exists that indicates no or few mutations are truly neutral 
(though most mutations are near neutral). Clearly negative or harmful mutations are often effectively 
eliminated from the gene pool, and it is the “near-neutral” mutations that are causing mutational 
meltdown. Depending on the specific set of mutations, near-neutral mutations can accumulate 
only to a certain level before they are collectively lethal. It is concluded that the accumulation of 
mutations is a major problem for Darwinism because the large number of near-neutral mutations that 
are not readily selected out of the gene pool accumulate in each generation, eventually causing 
extinction. Mutations, rather then being the engine that drives evolution upward, are, instead, causing 
degeneration of the genome. Evolution is occurring, but going the wrong way, as predicted by the 
creation model. The reasons why mutations are accumulating in the genome are discussed in some 
detail.
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Introduction
Mutations are widely recognized as a major cause 
of disease. In a review of the mechanisms that drive 
genetic degeneration, Charlesworth and Charlesworth 
concluded that “most mutations with observable 
phenotypic effects are deleterious” (1998, p. 3). 
Estimates vary, but generally, around one new mutation 
occurs in “each round of cell division, even in cells with 
unimpaired DNA repair and in the absence of external 
mutagens” (Meisenberg & Simmons, 2006, p. 153). As 
a result, “every child is born with an estimated 100 
to 200 new mutations that were not present in the 
parents” (Meisenberg & Simmons, 2006). Sanford 
(2005) puts the number of point mutations at about 
200 and all types total at closer to 1,000.
Of these “an estimated one or two new mutations 
are ‘mildly detrimental’,” meaning they do not cause 
disease but can impair physiological functions to 
some degree, contributing to multifactorial disease 
(Meisenberg & Simmons, 2006, p. 153). The result is 
that on average every child has “new mutations on 
top of those inherited from their parents” causing an 
accumulation of mutations, increasing the mutational 
load and, eventually, causing genetic meltdown and 
extinction (Higgins & Lynch, 2001).  
Potential evidence that the mutational genetic load 
in humans is increasing includes data recorded in 
the standard list of genetic diseases titled Mendelian 
Inheritance in Man. The first edition listed 1,487 
genetic diseases, the current edition over 17,000 
(McKusick, 1966, 1998). Several reasons exist for this 
dynamic increase, including the recent identification of 
existing genetic diseases, a larger human population 
that allows for more mutations of all types, and 
increased medical research in third-world nations.
The increase also reflects, in part, a real increase in 
the total number of mutations in the human genome 
(Bataillon, 2000). This paper reviews the empirical 
evidence for this latter conclusion.
Near-Neutral Mutations  
The core mechanism  of evolution is the occurrence 
of mutations that are selected by natural selection—if 
the mutation confers a competitive advantage to the 
organism (Sanjuán, Moya, & Elena, 2004, p. 8396). 
Mutations that have “large deleterious effects” are 
often effectively selected out. Conversely, those 
“mutations with small effects are . . . less efficiently 
eliminated from the population” (Sanjuán, et al., 2004). 
As a result the “accumulation of weakly deleterious 
mutations” produces a “substantial . . . long-term rate 
of fitness decline” (Barton, Briggs, Eisen, Godstein, & 
Patel, 2007, p. 494). Most mutations were at one time 
thought to be neutral, that is, they have no adverse 
effects on the organism. As will be discussed, it is 
now known that many or most of these mutations are 
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not completely neutral, but are actually near neutral 
or “very slightly deleterious” for several reasons 
(Kondrashov, 1995). No mutation is really neutral if 
it causes a deviation from the amino acid set produced 
by the original gene because it always results in a 
change in the protein’s original amino acid chain. 
The neutral mutation concept was considered 
a “radical and highly controversial new view of 
mutations” when proposed in the 1960s by Motoo 
Kimura, (Lowenstein & Zihlman, 1998, p. 190). 
However, this view soon became widely accepted 
and was assumed to be valid for “the vast majority 
of mutations.” The view that neutral mutations 
have “little or no effect” on an organism has been 
increasingly challenged in recent years. It is now 
known that even those mutations that have “little 
effect” on health can accumulate, causing major 
damage (Ohta, 1998; Sanford, 2005). Furthermore, 
evidence has accumulated that many putative 
neutral mutations are, in fact, not neutral, including 
the mutations in noncoding DNA that was once called 
junk DNA (Lowenstein & Zihlman, 1998). Among 
the studies that have found mutations in introns that 
cause disease (thus having a function) is included an 
intron in the calpain-10 gene that is associated with 
type II diabetes mellitus (Horikawa et al., 2000) 
Research on near-neutral mutations, summarized 
by Lynch, Conery, and Bürger (1995b, p. 1067) has 
established that it is “now generally accepted that 
mildly deleterious mutations arise at a substantial 
rate in most higher organisms, probably as frequently 
as one per gamete”. The number of known near-neutral 
mutations is enormous (Eyre-Walker, Keightley, 
Smith, & Gaffney, 2002). In human hemoglobin alone, 
close to 800 structural variants have been identified, 
most due to a single amino acid substitution and most 
of which are near neutral (Meisenberg & Simmons, 
2006, p. 163). The number of existing mutations 
that do not cause protein structural variations are 
unknown, but the number is probably many times 
greater than those that cause structural changes. 
Also, known structural variations may be caused by 
more than one mutation.
Why Neutral Mutations are not Neutral
Some of the neutral mutations studied were those 
occurring in non-coding DNA, often called junk DNA.
Coding DNA consists of only an estimated one to 
three percent of all DNA, or about one inch of the six 
feet of DNA in each human cell (International Human 
Genome Sequencing Consortium, 2004; Meisenberg 
& Simmons 2006). It is now widely acknowledged 
that many mutations in the alleged “junk” DNA are 
not neutral because much of it serves some function, 
including regulation, the assembly plans, and the 
control systems of the cell and the entire organism. 
Evidence for the importance of noncoding DNA is 
that it is highly conserved, indicating that much—or 
most of it—is functional (Gibbs, 2003).
It was once thought that these mutations were largely 
neutral. For example, components of the blood clotting 
system called fibrinopeptides function as spacers to 
keep the sticky molecular surfaces apart until a clot is 
required. The spacers are then removed and recycled, 
allowing the active protein form to exist. Though they 
function only as spacers, their specific composition can 
affect the clotting system effectiveness. Experimental 
evidence has found that the former conclusion that 
almost any amino acid will perform a spacer function 
equally well is incorrect for several reasons, including 
that certain amino acids can interfere with proper 
folding (Minshull, Ness, Gustafsson, & Govindarajan, 
2005). Mildly deleterious mutations in mitochondrial 
and chloroplast genomes, and also in transfer RNAs 
(tRNAs) and ribosomal RNA, gradually accumulate 
in the genome, and both contribute to mutational 
meltdown (Lynch & Blanchard, 1998, p. 29). This 
accumulation has been documented in a wide variety 
of life-forms including animals, plants, fungi, and 
prokaryotes (Lynch & Blanchard, 1998).
Synonymous Codons
Another major mutation group once felt to be 
neutral is a class called “synonymous” mutations.
One example is the putative neutral mutation that 
changes a codon, such as UCU which codes for serine, 
into a new codon, including UCC, UCA, and UCG, 
each of which are also translated into serine. The 
translation occurs because of the so-called wobble 
effect caused by the common third base redundancy.
As many as six codons will produce the same amino 
acid, and most amino acids can be coded by at least 
three synonymous codons. 
The new wobble codon is rarely lethal, but it is often 
slightly less effective. One reason why it is less effective 
is the fact that tRNA production levels often correlate 
with the original codon requirements, and a change 
causes tRNA supply imbalance problems.If a cell rarely 
uses a specific codon, it produces lower levels of the 
tRNA needed for that codon (Clark & Russell, 1999, 
p. 220). For this reason, a strong positive correlation 
exists between codon usage levels and tRNA content 
in a given organism (Ikemura, 1985). Consequently, 
athough the protein produced does not change, cellular 
efficiency does. This problem, called codon usage bias, in 
which a certain codon from the functional set is favored, 
is clear evidence for non-neutrality of synonymous 
substitutions. Another finding is that synonymous 
substitutions can change the structure and function of 
the final protein (Minshull et al., 2005). 
Further evidence that codon mutations are not 
neutral includes the fact that genes with high 
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codon usage bias “have lower rates of synonymous 
substitution between species then do genes with low 
codon usage bias” (Powell & Moriyama, 1997, p. 7785). 
An example is lysine, which can be coded by AAA or 
AAG. In E Coli, the AAA codon is used 75 percent of 
the time, and in rhodobacteria the opposite is true—
AAG is used 75% of the time. If a gene with a large 
number of AAA codons for lysine is transfected into a 
cell that almost never uses the AAA codon, its tRNA 
is then in such short supply that protein synthesis 
for that gene will slow down significantly (Clark & 
Russell, 1999, p. 220). This indicates that both tRNA 
regulation and the genetic code must have been in 
place simultaneously in order for the cell to function.  
Another example of non-neutral mutations are the 
six different codon triplets that code for leucine in E. 
coli, 49 percent of which are CTG; in yeast 10 percent 
of leucines use this code compared to 44 percent in 
the fruit fly and 41 percent in humans. This effect is 
another example of codon usage bias where a cell uses 
a particular codon only rarely: it produces lower levels 
of tRNA for that codon. In almost every organism 
studied so far, codon usage bias exists for a particular 
codon for each amino acid (Eyre-Walker et al., 2002; 
Ikemura, 1985; Moriyama & Hartl, 1993).  
Codon usage bias, which is one example of non-
neutral mutations that can have long-term deleterious 
effects, does not conform to neo-Darwinian 
predictions. If certain codons from the functional set 
were not favored, that is, if the proportion of codon 
usage were the same for all bacteria (which it is not), 
this could be seen as evidence for evolution. But we do 
not see evidence of a neo-Darwinian relationship in 
this pattern; in fact, we often find that two organisms 
judged close by evolutionary phylogeny do not have a 
similar coding usage bias compared with those judged 
phylogenetically distant. 
Neo-Darwinists argue that the codon evolved first, 
and the tRNA regulation system evolved later. But 
it could just as well be argued that tRNA regulation 
developed first, and this influenced the protein codon 
selection so that more of certain tRNAs influenced the 
codon used by that tRNA to become more common. 
Nonetheless, no evidence exists that a change has 
occurred historically in either codon frequencies or in 
tRNA regulation.
The codon usage bias level varies among organisms. 
For some amino acids in some organisms, its effect 
is large enough to impact the animal’s survival. 
Research indicates that, with the exception of aspartic 
acid, most amino acids contribute significantly, and 
about equally, to the codon usage bias effect (Powell 
& Moriyama, 1997, p. 7784). As these near-neutral 
mutations accumulate, overall cellular efficiency 
slowly declines, resulting in an overall negative effect 
on the fitness of an organism. 
Founder Mutations
Other evidence for a mutational meltdown 
includes founder mutations (Drayna, 2005). Founder 
mutations are disease-causing mutations that are 
not effectively eliminated by natural selection. As a 
result, the mutation persists in the population and 
can even become widespread, such as the mutation 
responsible for sickle cell anemia (Biswas, 2006).
The ancestor that suffered the first mutation, 
introducing the mutation into the gene pool, is known 
as the “founder.” Although often lost in history, some 
founders have been traced to a general geographical 
location. The most studied founder mutations have 
been traced to specific populations such as the Amish, 
Jews, Dutch, and Gypsies (Ben-Yosef & Friedman, 
2003; Jääskeläinen et al., 2004; Levine et al., 2003; 
Navarro & Teijeira, 2003; Zeegers, van Poppel, 
Vlietinck, Spruijt, & Ostrer, 2004).  
Documented cases of founder mutations include 
certain forms of holocarboxylase synthase deficiency 
disease (Suzuki, Yang, Aoki, Kure, & Matsubara, 
2005), mucolipidosis type IV disease (Bach, 2005), 
hereditary nonpolyposis colorectal cancer (Guillem, 
2004), early-onset Parkinson’s disease (Hedrich et al., 
2004); familial Mediterranean fever (Touitou, 2001) of 
which five founder mutations account for all 74 cases 
studied; Hermansky-Pudlak Syndrome (Huizing & 
Gahl, 2002); BRCA1 and 2 ( Liede & Narod, 2002; 
Lonning et al., 2001; Rubinstein, 2004;) hypertrophic 
cardiomyopathy (Jääskeläinen et al., 2006), 
hereditary paraganglioma (Baysal, 2004), Crigler-
Najjar Syndrome, and canavan disease (Surendran, 
et al., 2003). Yet another is factor V Leiden, an 
important risk factor in various thromboembolism 
diseases (Rees, Cox, & Clegg, 1995).  
The study of founder mutations has proven 
important in a variety of genetic studies (Rosenberg, 
2003). Founder mutations are most likely to persist in 
the population if the mutation is recessive, especially 
if a recessive copy can confer some advantage to the 
carrier, such as is the case with sickle cell anemia and 
cystic fibrosis disease, in which a CTT deletion accounts 
for virtually all cases of the disease in humans.
Several founder mutations can contribute to 
one disease. For example, at least five different 
haplotypes exist for sickle cell anemia, lending strong 
evidence to the hypothesis that at least five founders 
exist (Allison, 2002, p. 285). Another good example 
is hemochromatosis, caused by a mutation on the 
HFE gene on human chromosome six that disrupts 
the iron regulation system. This causes excessive 
iron absorption, eventually leading to organ damage 
and even death if not treated. The mutation evidently 
originated in central Europe about 65 generations 
ago, and is now present in at least one of the two HFE 
genes in an estimated 22 million Americans.
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Many founder mutations persist because they do 
not affect the victim until after childbearing years. 
An example is the trinucleotide repeat disorder called 
Huntington’s Disease, a condition that now affects 
many thousands of persons. Traced back to at least 
1630, it is now known, thanks to the work of Dr. 
Nancy Wexler, that the gene was brought by a few 
individuals to both North and South America. Because 
it is a dominant gene, on average it affects about 
half of all offspring of couples, of which at least one 
partner is a carrier. This neurodegenerative disease 
causes gradual dementia, uncontrolled movements, 
and eventually death (Duyao et al., 1993).  
The symptoms of Huntington’s Disease usually do 
not show up until after the fourth or fifth decade of 
life, after normal reproductive years are past. Many 
carriers, due to genetic testing, are now aware they 
have the gene in their family. Some victims, knowing 
that about half of their children will develop the 
lethal disease, still elect to have children. Founder 
mutations are significant examples of deleterious 
mutations because before these mutations entered the 
human genome, the diseases they cause did not exist. 
As founder mutations accumulate in a species, the 
accumulation contributes to the degeneration of the 
genome, especially a problem for those species with 
small population sizes (Keightley & Eyre-Walker, 
2000; Sanford, 2005).
Genetic Drift and Interbreeding Depression
Another problem contributing to genetic meltdown 
is random genetic drift that allows near-neutral 
mutations to spread to an entire population, 
increasing the probability of the “extinction of 
the whole population, or the degeneration of non-
recombining portions of the genome” (Charlesworth 
& Charlesworth, 1998, p. 3). This is especially 
problematic in both small populations andpopulations 
that would typically outbreed but do not for forced or 
self-imposed reasons, such as the Amish, a religious 
group that is known to suffer from a large mutational 
load. As a result from founder mutations, the Amish 
“experience an inordinately high incidence of certain 
genetic-based diseases,” many of which are fatal or 
disabling (Shachtman, 2006, p. 24). An example is 
Crigler-Najjar syndrome, a genetic disorder that is 
caused by high levels of bilirubin, which produces 
severe jaundice, resulting in brain damage and death. 
The specific cause is a damaged liver enzyme that is 
part of the metabolic breakdown pathway of bilirubin. 
Worldwide, fully 20% of all cases are found in the tiny 
Amish population (Morton, et al., 2003).  
Selection reduces their mutational load—Amish 
families often lose one or more children to genetic 
diseases—yet the mutational load keeps increasing.
Often genetic diseases, such as many metabolic 
disorders, can be treated, allowing those so afflicted 
to reach the age of sexual maturity and pass the 
mutations on to their offspring. In 1988, three dozen 
major genetic diseases were identified among the 
Amish; now fully five dozen are known (Shachtman, 
2006, p. 28).
   
Are Polymorphisms Just Variety?
Another example of deleterious mutations is 
certain genes that were all once assumed to be an 
example of normal variety. Some or possibly many of 
these genes called polymorphisms (about one percent 
of the genome) may be near neutral or even harmful 
mutations and not just normal variations (Nachman, 
1998, p. 61). As more polymorphisms are researched, 
it has been found that some examples once regarded as 
normal variations are mildly deleterious. For example, 
blue-eyed and fair-skinned persons are significantly 
more prone to skin cancer, even in environments 
where it was assumed that these traits were important 
in survival, such as locations where an increased 
vitamin D production is beneficial. Blue eyes are 
caused by lack of pigmentation on the iris, and blue-
eyed persons are more prone to certain eye problems, 
such as difficulty working in bright environments, 
retinal pigment epithelial depigmentation, and other 
vision problems (Acosta, Alfaro, Borras, Belmonte, 
& Gallar, 2006; Singh, Rennie, Seregard, Giblin, & 
McKenzie, 2004; Tomany, Klein, & Klein, 2003).  
Redundancy in Life
Yet another reason why most mutations are 
rarely (if ever) neutral is because of the redundant 
systems in most life-forms. Survival, at least to the 
point of reproduction (the key to natural selection), is 
rarely affected in cases where a backup organ exists 
(the phenomena of organ redundancy). Humans 
can normally survive quite well without tonsils, 
adenoids, spleen, appendix, one kidney, or a lobe of 
the liver, allowing mutations that affect these organs 
to be passed on to one’s offspring and become part 
of the human genome. If a mutation damages an 
organ, redundancy allows a considerable number of 
mutations to accumulate that will only be weakly 
selected against.  
Another redundancy factor is the fact that all 
sexually reproducing organisms possess two copies 
of most genes. If one gene mutates, the other allele 
on the sister chromosome can produce the correctly 
folded protein. The single copy condition allows 
mutations to accumulate because the mutation that 
is not effectively selected out if the other gene can still 
perform the sister gene’s function. This redundancy 
allows damaged genes to accumulate in the genome, 
contributing to the mutational meltdown problem. 
If humans were haploid, a normal gene mate would 
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not be present to compensate for a damaged gene, 
and the affected person would be more likely to die 
early without passing genes on to offspring. As these 
near-neutral mutations accumulate, the strain on the 
system increases.  
Although redundancy often allows survival, 
heterogeneous mutations can affect dosage levels, 
requiring compensation. Recessive mutations may 
also damage the working unit. For example, the p53 
transcription factor is a tetrad of four p53 proteins, 
and if even a single protein in the tetrad is damaged, 
the transcription factor will not function. Despite this, 
recessive germline p53 mutations are often not lethal 
until after having children. Familial p53 mutation 
patients (Li-Fraumeni Syndrome) usually die of 
cancer but can live into, and even past, childbearing 
age, allowing them to pass the mutation on to their 
offspring (Vogelstein & Kinzler, 1998, pp. 398–399). 
Redundancy is not always an advantage, such as is 
the case with triplet repeat expansion disorders and 
possibly some co-dominance genetic conditions.
The fact that most known human genetic disorders 
are recessive explains how the mutations are passed 
on to the next generation. Some well-known examples 
include cystic fibrosis, sickle cell anemia, and Tay-
Sachs disease. Since a person must have both genes 
in order to have the disease, only a small portion of 
the affected population will die from the disease, 
allowing others with the mutation to pass it on. 
Evidence for this conclusion is the high frequency 
of many recessive mutations in the population. For 
example, among Greeks, factor V Leiden is present 
in around 7% of the population (Rees, Cox, & Clegg. 
1995, p. 1133). Cystic fibrosis strikes thousands each 
year; about one in every 20 Caucasian Americans (a 
total of 12 million persons) is a carrier of an abnormal 
CF gene; most are unaware that they are carriers. 
Among blacks, about 7.8% are sickle cell anemia 
carriers, and about 0.15% actually have sickle cell 
disease (data from NIH Publication No. 95-3650). 
Lethal Mutations that have 
Selective Advantages
Lethal or deleterious mutations are actually 
selected in certain circumstances. The most common 
examples actually encourage the spread of lethal 
mutations, contributing to the accumulation of 
mutations in the genome. The classic example of a 
generally harmful mutation that can have a beneficial 
effect in specific situations is sickle cell anemia 
(Ridley, 1996, p. 118). The homozygous form is lethal, 
causing approximately 100,000 deaths annually, but 
the heterozygous form provides a survival advantage 
where malaria is common. The heterozygote form, 
although it causes anemia, does not result in a level 
of sickling that significantly affects blood circulation. 
For this reason the mutation is said to be latent.  
If the malaria parasite Plasmodium falcipurum 
infects an erythrocyte, the victim with a heterozygote 
mutant form is more likely to survive. It has been 
well documented that persons with one damaged 
gene survive better in areas of the world where the 
malaria parasite is common. The parasite feeds on the 
hemoglobin molecule, causing the oxygen concentration 
in the cell to decline, resulting in sickling of the infected 
cell. Sickling in turn causes that cell (and the malaria 
parasite in it) to be destroyed by the spleen (Ridley, 
1996, p. 118). Many other examples of heterozygous 
mutations exist that provide a selective advantage in 
limited conditions but would be selected out in most 
circumstances. Examples include some thalassemia 
herterozygotes, which provides an advantage against 
malerial parasites as does the sickle cell allele; the 
CCR5 deletion, which gives some protection from 
AIDS; and glucose-6-phosphate dehydrogenase 
variant (G6PD-Mediterranean). G6PD deficiency, a 
condition  characterized by severe enzyme deficiency, 
but confers some resistance to falciparum malaria. 
(Beutler, 1996; Kurdi-Haidar et al,1990). 
Methylation of DNA
Methylation of DNA is a major means of controlling 
gene expression. Methylation is used for significant 
genetic regulation to achieve cellular differentiation 
and dosage compensation, such as lyonization in 
females, which silences one X chromosome. Specific 
methylation sites are a heritable phenomenon that 
selectively reduces gene expression by increasing the 
binding of repressors. Alterations of methylation sites 
can be passed on to future generations and therefore 
contribute to the degeneration of the genome.  
Methylation is also a major means of causing gene 
imprinting to achieve sexual differentiation by turning 
off one set of somatic genes in males and another set in 
females (Baysal, 2004). Changes in methylation can 
adversely affect all of these critical genetic functions. 
Disruption of methylation is not effectively repaired, 
allowing loss of this epigenetic means of control to 
accumulate and, in time, contributing to genetic 
meltdown.
CpG islands are a region of 1–2 kb sequences 
containing a high density of methylated cytosine 
residues. In plants, fungi, and animals, it is the 
cytosines are usually methylated, but in bacteria 
the adenosines are normally methylated (Turner, 
2007, p. 214). In plants, the methylated sequence is 
... CpNpGp ... where N can be any base. CpG islands 
are a site of high mutational frequency because 
spontaneous deamination of the methylated cytosine 
5-methylcytosine results in thymine, which is not 
recognized by DNA repair enzymes and unrepaired, 
resulting in genomic degradation (Coulondre, Miller, 
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Farabaugh, & Gilbert, 1978). Approximately 5% of 
vertebrate DNAs consist of 5-methylcytosines, and 
with time more and more conversion of C to T occurs 
by this process.  
Modern Medicine
Modern medicine can contribute to genetic 
degeneration because it may allow children that have 
lethal mutations to live long enough to reproduce, 
increasing the human mutational load. The mutational 
load is thus reduced by natural selection and increased 
by modern medicine. Historically in many societies 
as many as half of all children died before they were 
old enough to reproduce. Those who died had, on 
average, not only more detrimental mutations, but 
also more near-neutral, detrimental mutations than 
those who survived. Medicine, antibiotics, and better 
nutrition and sanitation have reduced this death rate 
significantly (Meisenberg & Simmons, 2006, p. 153). 
Darwin recognized this concern and for this reason 
opposed vaccinating because the procedure 
has preserved thousands, who from a weak 
constitution would formerly have succumbed 
. . . . Thus the weak members of civilized society 
propagate their kind . . . this must be highly injurious 
to the race of man. It is surprising how soon a 
want of care, or care wrongly directed, leads to the 
degeneration of the domestic race . . . we must bear 
without complaining the undoubtedly bad effects 
of the weak surviving and propagating their kind 
(1871, pp. 168–169).
Although Darwin’s example is incorrect because 
infectious disease effects largely those with weak 
immune systems or those who lack resistance), his 
point is valid with many diseases. This point does not 
condemn the use of modern medicine as Darwin did, 
but recognizes the fact that an unfortunate side effect 
is that medicine has reduced enormously the infant 
mortality rate, allowing persons with detrimental 
mutations to have offspring and pass them on to 
future generations. Lynch, et al., opines that with 
animal life the problem of deleterious mutation 
accumulation may be exacerbated in endangered 
species that are confined to breeding facilities. Since 
captive environments are usually quite benign 
(including services from dietitians, veterinarians, 
artificial inseminators, etc.), a real possibility exists 
that mutations that are significantly deleterious in 
nature are rendered nearly neutral. If that were the 
case, regardless of the population size, deleterious 
mutations would accumulate at nearly the neutral 
rate, µ/2 per generation, although their effects would 
go undetected until the population was reintroduced 
into the wild. At that point, the population might no 
longer be capable of sustaining itself without continued 
human intervention (Lynch, 1996, p. 489).
Mutations Compensated for by 
Dietary Alterations
An important class of mutations are those that 
damage an enzyme, a metabolic pathway, or a mediated 
transport system that moves materials across a cell 
membrane. Many of these mutations cause diseases 
that can be successfully treated by dietary changes, 
allowing the patient to survive and pass the mutation 
on to their progeny. The most well-known example 
is phenylketonuria (PKU), a metabolic disorder 
that results in the buildup of toxic byproducts from 
the defective breakdown of phenylalanine. PKU is 
successfully treated by a rigid dietary restriction of 
phenylalanine, an essential amino acid (Meisenberg 
& Simmons, 2006, p. 494). 
Newborn screening for PKU is mandatory in 
many countries. The disease, which, depending 
on the mutations involved, normally causes severe 
retardation, seizures, spasticity and other neurological 
problems that prevent the victim from passing the 
mutation on to offspring. However, by following 
dietary restrictions, PKU patients now develop 
normally and can freely pass the mutation on to their 
offspring (Meisenberg & Simmons, 2006, p. 494). 
Although phenylalanine is nutritionally essential 
in small amounts, it can be greatly reduced by such 
dietary restrictions such as avoiding the artificial 
sweetener aspartame and other foods and condiments 
that contain large amounts of phenylalanine without 
adverse health effects. Again, the human and proper 
response has unintended undesirable side effects.
Some other examples of the many known metabolic 
diseases caused by mutations include trypsinogen 
deficiency treated by dietary supplementation of 
protein hydrolysate and celiac disease treated by a 
gluten-free diet (Frezal & Rey, 1970, pp. 287–288). 
Gluten, found in wheat, rye, and barley, can be avoided 
by not eating foods containing these grains. Other 
examples include milk protein intolerance treated 
by complete avoidance of cow’s milk. Depending 
on the specific mutation involved, the problem is 
often an inability to process casein and lacto-serum 
proteins. Another example is sucrose and isomaltose 
intolerance, usually treated simply by removal of 
sucrose and starch from the diet. Most of these 
diseases are lethal if not treated, and the cause of 
most of them was unknown until recently (Frezal & 
Rey, 1970, p. 306). 
Mobile Elements Damage the Genome
Much of our genome is currently believed to 
contain what is often, and probably incorrectly, called 
“parasitic DNA,” which are a result of what is known as 
jumping genes or—more formally—mobile elements. 
How many of the mobile elements cause damage 
is not known, but the fact that the DNA in our 46 
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chromosomes, some conclude, contains an estimated 
three million mobile DNA segments indicates the 
damage may not be minor. This mobile DNA includes 
retroviruses—a type of retrotransposon similar 
to the AIDS virus. Other examples include Long 
Interspersed Elements (LINES) or Short Interspersed 
Elements (SINES). Research evidence indicates that 
some retrovirus LINES and SINES have vigorously 
colonized the DNA of mammals. LINES use two 
genes of their own, and SINES, which do not have 
genes to splice themselves into the genome, must 
instead hijack the enzymes of other putative parasites 
in order to copy and paste themselves into new DNA 
sites (Kazazian, 2004, p. 1626). Even if most all of 
the parasitic DNA is found to have a use, the small 
amount of misplaced or actual parasite DNA could do 
a significant amount of damage.
These mobile elements normally insert themselves 
into DNA at selective sites but sometimes insert 
themselves at other sites, disrupting a gene and causing 
a mutation. An estimated one in every 200 babies has 
inherited a new damaging putative parasitic element, 
and one in every 1,000 patients has a new genetic 
disease as a result of a misdirected mobile element 
that has disrupted an important gene (Ostertag & 
Kazazian, 2001; Deninger & Batzer, 1999; Ostertag, 
Goodier, Zhang, & Kazazian, 2003). Assuming that 
these estimates are correct, this damage will result 
in a significant increase in the mutation load.
Some cancer-causing viruses also splice themselves 
at random sites into human DNA. When a particular 
viral DNA section is found at the same position in 
the DNA in every cell in a cancer tumor, all of those 
cells are believed to be descended from the cell in 
which the unique viral insertion occurred—the 
founder mutation (Ng, Guan, Poon, Fan, & Lee, 2003; 
Tsukaski, Koeffler, & Tomonaga, 2000). Some common 
examples include papilloma viruses, hepatitis, and 
some forms of leukemia. Founder mutations caused 
by mobile element insertion errors are not reversed by 
any known dedicated mechanism, and, unless lethal 
before reproduction, they accumulate in the genome, 
contributing to genetic degeneration.
Another example is the Alu elements that are 
amplified by retrotransposition, an RNA-dependent 
mechanism. Although they are believed to be 
functional in humans, they continue to accumulate 
at the rate of one insertion for every 200 new 
births (Deininger & Batzer, 1999, p. 183). At least 
16 new diseases have been identified as being 
caused by new Alu elements, including hemophilia, 
neurofibromatosis, chlorinesterase deficiency, 
glycerol kinase deficiency and several cancers 
(Deininger & Batzer, 1999, p. 184). Alu elements 
alone may cause as much as 0.4% of human genetic 
disease. Another major mobile unit of DNA is the L1 
element, which is much longer then Alu elements. L1 
elements can also supply the needed components for 
Alu retrotransposition.
Tandem Repeat Expansion Disorders
Many genes consist of repeats of sets of three or 
more bases called tandem repeat bases. They tend 
to be mutational hot spots (Sutherland & Richards, 
1995). The “length of tandem repeats is prone to 
change through mutation,” and in each generation they 
can increase, a problem called stuttering, eventually 
causing disease because the expanded protein forms 
abnormal complexes with other proteins (Meisenberg 
& Simmons, 2006, p. 127). For example, Huntington’s 
disease is caused by an expansion of the CAG 
trinucleotide repeat. CAG is normally repeated from 
6–34 times and causes disease if it expands beyond 36 
repeats. The repeat often expands in each generation, 
and the more it expands, the earlier the onset of the 
disease. Other common examples of tandem repeat 
disorders are fragile X syndrome, Friedreich ataxia, 
and myotonic dystrophy (Campuzano, et al. 1996; 
Hagerman & Cronister, 1996; Mahadevan, M., et al. 
1992)
Pseudogenes
Evidence indicates that many pseudogenes are 
damaged genes. For example, most animals (except 
humans, apes, monkeys, fruit bats, several species of 
fish, and guinea pigs) can manufacture an enzyme 
that is critically important in vitamin C production.
The L-gulono-gamma-lactone enzyme catalyzes 
the last step of vitamin C synthesis (Nishikimi, 
Fukuyama, Minoshima, Shimizu, & Yagi, 1994). 
Lack of about 60 mg of vitamin C daily in humans 
leads to serious health problems, including scurvy, 
which has historically been a major killer.
Humans possess all of the enzymes required to 
manufacture vitamin C except L-gulono-gamma-
lactone (Inai, Ohta, & Nishikimi, 2003). A pseudogene 
that is about 70% similar to the functional gene 
exists that appears to be a damaged L-gulono-
gamma-lactone gene. Specifically, it lacks critical 
control sequences, such as the promoter, required 
to transcribe the gene (Zhang, Harrison, Liu, & 
Gerstein, 2003). The human pseudogene has four of 
the 12 exons of a similar functional L-gulono-gamma-
lactone gene in the rat. These four rat exon sequences 
have 70–80% homology to the human pseudogene. 
If this pseudogene is, in fact, a damaged functional 
gene, its loss has resulted in an enormous number 
of human deaths. Of the thousands of pseudogenes 
believed to exist, no doubt, some do have a function, 
such as for genomic regulation, but it is likely that 
some are damaged functional genes. No one knows 
how common pseudogenes are, and estimates vary 
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widely, but they are believed to be very common. 
Gerstein and Zheng claim that they “litter our 
chromosomes” (2006, p. 49). This is evidence for a 
genetic meltdown instead of the genetic build-up that 
is required by evolution.
Genetic Meltdown Evidence
These few examples illustrate why the 
accumulation of near-neutral mutations contributes 
to the “mutational meltdown” problem, eventually 
causing extinction (Lynch, Conery, & Bürger, 1995a, 
b; Eyre-Walker & Keightley). As early as 1964 Muller 
proposed that even very large populations of asexual 
organisms would inevitably accumulate deleterious 
mutations (Barton, Briggs, Eisen, Goldstein, & Patel, 
2007, p. 681). Muller concluded that the result would 
be a gradual ratchet-like increase in mutations, 
eventually causing the extinction of the organism, an 
effect called “Muller’s ratchet” (Muller, 1964).  
Muller concluded that the accumulation of 
deleterious mutations eventually results in the 
extinction of even the most fit organisms. This 
problem is most serious in asexual organisms and is 
exacerbated by both a high mutation rate and small 
populations. The reason is “in the absence of sex, 
deleterious alleles accumulate” because sex produces 
recombination as a result of genes from each parent. 
Furthermore, all 
populations must continually eliminate deleterious 
mutations if they are to survive. This elimination 
is much more efficient if there is recombination . . . . 
[T]he primary function of sex and recombination may 
be to prevent the fatal accumulation of mutations. 
Because all organisms suffer a mutation load, this is 
an attractive general explanation for the prevalence of 
sex and one that has received much attention in recent 
years. Sexual reproduction can reduce the mutation 
load . . . . If mutation is always from good alleles to bad 
(a reasonable approximation) then the fitness of an 
asexual population is reduced . . . if there is negative 
epistasis, so that the effect of each additional mutation 
becomes more severe as the number of mutations 
increases, then negative linkage disrequilibria will 
be generated. Recombination breaks these up and, by 
doing so, can substantially reduce the mutation load. 
This gives a population-level advantage for sexuals 
over asexuals (Barton, et al., 2007, p. 680). 
In a typical study of the mutational load problem 
that examined 1,700 generations, Andersson and 
Hughes found 1% of the 444 lineages of a DNA based 
microbe studied “had suffered an obvious loss of 
fitness” (1996, p. 906; Nachman & Crowell, 2000). 
The researchers concluded that genetic mechanisms 
in asexual populations, such as back mutations or 
compensatory mutations, “cannot compensate for the 
accumulation of deleterious mutations” (1996, p. 906). 
Lynch et al. concluded that, although it is “widely 
acknowledged that the gradual accumulation of 
mildly deleterious mutations is an important source 
of extinction for asexual populations,” evidence now 
exists to support the conclusion that the gradual 
accumulation of near-neutral mutations causes the 
same result in sexual populations (1995b, p. 1067). 
They add that computer simulations supported by 
analytical approximations  
indicate that mutation accumulation in small, 
random-mating monoecious populations can lead 
to mean extinction times less than a few hundred 
to a few thousand generations . . . . Under all mating 
systems, the mean time to extinction increases 
relatively slowly with the logarithm of fecundity, 
and mutations with intermediate effects (similar to 
those observed empirically) cause the greatest risk of 
extinction” (Lynch et al., 1995a, p. 1067).
A study of the mechanisms that purged fixated 
deleterious genes noted that “a large fraction of 
mutations” are “unconditionally deleterious” (Lynch, 
1996, p. 483). Lynch added that the “accumulation of 
deleterious mutations” influences the mean fitness 
and extinction risk, especially of small populations. 
He concludes that the “worst-case scenario is realized 
when the size of the founder population is so small 
that random genetic drift completely overwhelms 
the power of natural selection” (1996, p. 486). 
Slightly deleterious and near-neutral mutations 
also accumulate in mitochondrial DNA. Evidence 
now exists that “many mitochondrial amino acid 
polymorphisms are deleterious” (Nachman, 1998, 
p. 67). Random factors and genetic drift are also 
important. Barton et al., conclude
any kind of selection causes random fluctuations 
at linked loci, which may by chance fix deleterious 
mutations. This effect is especially severe in strictly 
asexual populations . . . even in a very large asexual 
population, deleterious mutations must accumulate 
[and even] . . . the fittest genotype can be lost by 
chance, and once lost, it can never be recovered . . . . 
[T]he whole population must trace its ancestry back 
to the fittest class . . . . Once the fittest class is lost, 
the process begins again, but with all individuals 
carrying one extra mutation. Even if the population 
size is in the millions, weakly selected mutants will 
still accumulate (Barton et al., 2007, p. 687).
Mutation Rates
To assess the contribution of near-neutral mutations 
to the mutational meltdown problem, understanding 
the rate of mutations is critical (Crow, 1997; Neel et. al., 
1986). The rate that mutations are expressed depends 
on a wide variety of factors, and this is one reason why 
the mutation rate can only be estimated (Kondrashov, 
1998). For example, the mutational expression rate is 
107Progressive Evolution or Degeneration?
higher in cases of self-fertilization and inbreeding, 
but lowed when  synergistic epistasis.  is involved.
Epistasis refers to the interaction between genes: 
synergistic is a positive interaction (higher expression 
of the trait), antagonistic a negative interaction 
(lower expression of the trait). Charlesworth and 
Charlesworth conclude that the mutation rate is so 
high that highly inbreeding species are expected to 
have a short existence (1998, p. 15). 
Andersson and Hughes found a deleterious 
mutation rate of 0.3 to 1.5 mutations per billion base 
pairs per generation in Salmonella typhimurium, 
which they characterized as having a “typical 
genomic mutation rate” for bacteria (1996, p. 906). 
Work on Drosophila suggests a rate of 0.5 mutations 
per generation that causes a reduction of fitness by 
one to two percent per generation (Charlesworth & 
Charlesworth, 1998, p. 15). This number is significant 
because bacteria and fruit fly generations consist of a 
matter of minutes or days. In the laboratory “rates 
of spontaneous mutation per genome as measured in 
the laboratory are remarkably similar within broad 
groups of organisms, but differ strikingly among 
groups” (Drake, Charlesworth, Charlesworth, & Crow 
1998, p. 1667). They estimated that in microbes the 
rate is 1/300 per genome per replication and in higher 
eukaryotes from 0.1 to 100 per genome per sexual 
generation. For mammals the mutational meltdown 
would be expected to take thousands of years. 
More recent research that obtained the first direct 
estimate of mutation rates in complex organisms 
found evidence that mutation rates are about 100 
times higher than previous estimates (Denver, 
Morris, Lynch, Vassilieva, & Thomas, 2000). Most of 
these studies ignored what were considered neutral 
mutations. The current estimate for all mutations is 
approximately one unrepaired mutation occurs for 
every one hundred million nucleotides copied each 
generation. With three billion base pairs in humans 
this equals a minimum of 30 new mutations per 
individual (Behe, 2007, p. 11). A literature review by 
Sanford (2005) found that the number of mutations 
is even higher. Barton et al. concluded that the total 
genome-wide  mutation number that changes amino 
acid sequences is about 0.9 per haploid genome per 
generation. If even a small proportion of these were 
only mildly deleterious, a significant number could 
accumulate. Although the “effect of each mutation 
would be small, the long-term rate of fitness decline 
could be substantial” (Barton et al., 2007, p. 494).
These studies indicate much work is needed in this 
area to understand different mutation rates found, 
which depend on the organism, where the mutation 
occurs in the gnome, the effectiveness of the repair 
system, and the effectiveness of natural selection 
to remove mutated organisms from the gene pool. 
Nonetheless, the rate is so significant that numerous 
researchers have explored the obvious question: why 
have we not seen a genetic meltdown in all life by 
now (Kondrashov, 1995)? A common answer is that 
natural and sexual selection both work to slow down, 
but not stop, the mutational load increase (Andersson 
& Hughes, 1996, p. 907). The genetic meltdown is 
proceeding forward, although far less rapidly then 
it would if selection and sexual reproduction did not 
exist. Meisenberg and Simmons note that the
mutational load is kept in check by natural selection. 
In most traditional societies, almost half of all children 
used to die before they had a chance to reproduce. 
Investigators can only guess that those who died had, 
on average, more “mildly detrimental” mutations 
than those who survived (2006, p. 153).
Mutational rates are misleading because the 
45,000–50,000 detected coding regions in humans 
produce over 100,000 different proteins due to 
alternative splicing (Bertone, et al, 2004). As a result, 
one mutation may result in several defective proteins. 
Furthermore, “it is likely that nearly all human genes 
are capable of causing disease if they are altered” in 
ways that produce defective proteins that affect their 
function (2002, p. 1514). The ENCODE project found 
that the same is true of mutations in the large number 
of regulatory DNA. The near-neutral mutations, and 
those that allow the afflicted to survive, can add to 
the total genetic load of near-neutral and deleterious 
mutations. Another factor is over one dozen mutation 
repair mechanisms are known to exist, and, no doubt, 
more await discovery. Research on persons exposed to 
radiation indicates that after several generations, the 
repair system and natural selection may reduce the 
mutation load. This effect tends to maintain stasis, 
an effect that opposes evolution.
Summary
The evidence shows that evolution by means of 
mutations, under the influence of natural selection, 
is real but, in the long run, results in degeneration 
of genomic information—not in an improvement as 
required by orthodox evolution. As Lynch concludes, 
assuming back mutations are rare and discounting 
the effect of recombination and segregation, a parent 
“can never produce an offspring with fewer deleterious 
mutations then it carries itself” (1994, p. 1067). The 
mutational load will, in general, increase with each 
generation, and since most all (if not all) mutations 
are either near-neutral or deleterious, the result will 
be genetic deterioration, eventually leading to genetic 
meltdown and extinction. Direct experimental 
genetic evidence of this conclusion has been found in 
laboratory research with Saccharomyces cerevisiae 
populations (Zeyl, Mizesko, Arjan, & De Visser, 2001). 
Both near-neutral and detrimental mutations were 
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evaluated, focusing on the reasons why detrimental 
mutations were not eliminated by natural selection.
Although only a small portion of all mutations 
in eukaryotes is detrimental enough to directly 
affect survival, the total number occurring in each 
generation is significant (Kondrashov, 2002). It was 
once concluded that the vast majority of all mutations 
were neutral, but evidence now exists indicating that 
few mutations are truly neutral: most mutations are 
near neutral (Sanford, 2005, p. 72). Clearly harmful 
mutations are often effectively eliminated from the 
gene pool, and it is the “near-neutral” mutations that 
are causing concerns about mutational meltdown of 
life because they accumulate in the genome. The most 
common example is aging, which is a result of an 
accumulation of mutations, but evidence now exists 
that the genome itself is also aging (Sanford, 2005).
This review confirmed Sanjuán’s conclusion 
that “mutations typically lead to reduced fitness,” 
but fortunately, many mutations are “removed by 
purifying selection” (Sanjuán et al., 2004, p. 8396). 
The problem is the near-neutral mutations—those 
that are not lethal and, for this reason, are allowed to 
accumulate in the gene pool. As Lynch concludes 
what little we know about deleterious mutations raises 
the real concern that their recurrent introduction can 
threaten the persistence of even moderately large 
populations over time scales of several dozens of 
generations (1996, p. 489).
This is because many factors intersect. For example, 
osteogenesis imperfecta, or brittle bone disease, is 
caused by mutations in the genes that make 1 pro-
collagen, both COL1A1 and COL1A2 genes. Although 
osteogenesis imperfecta is, in the vast majority of 
cases, inherited in a dominant fashion, its penetrance 
is variable, meaning the clinical characteristics and 
severity vary greatly (Plotkin, 2007). Most victims 
survive to adulthood and have families, and many 
patients with mild forms may not even be aware of their 
condition. Thus, the mutation is commonly passed on 
and has become a part of the human genome load. 
The disease can effect several organs and even whole 
organ systems, disproportionately contributing to 
the human mutational breakdown problem (Plotkin, 
2007). New mutations introducing the disease in new 
genetic lineages are fairly common, resulting in an 
increase in the rate of osteogenesis imperfecta in the 
population in addition to inherited cases.
Conclusions 
The main mechanism contributing to this meltdown 
is the “recurrent introduction of new deleterious 
mutations in each generation” (Lynch & Blanchard, 
1998, p. 29). The accumulation of mutations is a major 
problem for Darwinism, mainly because of the large 
number of near-neutral mutations that are not readily 
selected out of the gene pool. These accumulate in 
each generation, eventually causing extinction. It 
was found that certain clearly negative mutations 
are not selected out from the gene pool for at least a 
dozen reasons, and as a result they accumulate in the 
genome. Clear evidence now exists that mutations, 
rather then being the engine that drives evolution 
upward, instead are causing degeneration of the 
genome in harmony with the biblical concept of the 
Fall and Curse. Evolution, defined strictly as genetic 
change, does occur, and these changes are a critical 
component of the creation model that helps to account 
for the enormous biological diversity seen in the 
natural world today. However, the types of mutational 
changes discussed in this review are inconsistent 
with the evolutionary idea of common decent from 
ancestral protocells.
Science research has proven the following challenge 
wrong:
The church teaches that man was created perfect, 
and that for six thousand years he was degenerated. 
Darwin demonstrated the falsity of this dogma. He 
shows that man has for thousands of ages steadily 
advanced; that the Garden of Eden is an ignorant 
myth . . . and that man did not “fall” (Ingersoll, 1990, 
pp. 358–359).
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